SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022.
News
Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 13,333,334 shares… Click here to view original post… […]
News
Progenity to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 03, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in two upcoming virtual investor conferences: Click here to view original post… […]
News
Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on Thursday, August 12, 2021 after the close of financial markets. Progenity’s management will host a webcast and conference call at 4:30… Click here to view original post… […]
